Bristol Myers Squibb (BMS) announced a definitive agreement in which BMS will acquire Orbital Therapeutics along with its ...

How will pharma companies react to the administration's efforts? Dr. William Soliman: We’ve seen Pfizer doing a deal with Trump, and I think other companies will follow. If they can come to a ...

In the second part of Pharm Exec’s webinar series, experts discuss the changing landscape surrounding the MFN executive order ...

Regeneron's Libtayo gains FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, enhancing ...

Novo Nordisk acquires Akero Therapeutics to enhance its portfolio with efruxifermin, a promising treatment for metabolic ...

Shana Tetrault, PhD, Director of Product Marketing at Quanterix, outlined strategies for integrating blood-based biomarkers into routine clinical care pathways, ensuring minimal disruption for ...

Chris Spivey, Director of Industrial Relations and Strategic Partnerships for Industry Sciences One at MJH Life Sciences, and Raymond J. Deshaies, PhD, Executive Officer of Molecular Biology at the ...

In America, 80% of people on drugs are on generics. We talk a lot about pharma pricing, but the majority of people who are on multiple medications are on generics. For those drugs, you’re not going to ...

The deadline for DSCSA compliance is approaching. For many in the industry, this moment marks the end of a long regulatory ...

FDA approves Jascayd, the first new treatment for idiopathic pulmonary fibrosis in over a decade, significantly reducing ...

In today’s Pharmaceutical Executive Daily, we explore why medical AI success depends on more than algorithms, Amgen’s launch ...

In today’s Pharmaceutical Executive Daily, we cover the FDA lifting its clinical hold on Neurizon Therapeutics’ lead program ...